

In the News

Update to Commercial and ACA Medical Benefit Product Coverage for Medical Mutual Plans

Effective November 1, 2023 prior authorization will be required for Infugem (gemcitabine) [HCPCS code J9198] and Pemfexy (pemetrexed) [HCPCS code J9304] under the commercial and ACA medical benefit.

Gemcitabine hydrochloride (J9201), Alimta (J9305), Pemetrexed, Hospira (J9294), Pemetrexed, Accord (J9296), Pemetrexed, Teva (J9314), and Pemetrexed, Sandoz (J9297) will be managed by claims edit and no prior authorization will be required.

For more information, please visit [Medmutual.com/For-Providers, Policies and Standards, Medical Policies](https://www.medmutual.com/For-Providers-Policies-and-Standards-Medical-Policies).